These insights represent the first characterization of risk factors for respiratory failure–related hospitalization among patients with sarcoidosis‐associated pulmonary hypertension (SAPH). Newly ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window LOS ANGELES -- ...

In the last several years, there have been numerous advancements in the field of pulmonary hypertension as a whole, but there have been few changes in the management of children with pulmonary ...

The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no significant impact on exercise capacity in pulmonary fibrosis and pulmonary ...

Future Cardiol. 2013;9(3):335-349. The pivotal trial that established sildenafil as a treatment for WHO Group 1 PH was the SUPER trial. [102] SUPER enrolled WHO functional class II and III PAH ...

This drug causes pulmonary and systemic vasodilation, which positively affects hemodynamics, decreasing PVR and median pulmonary arterial pressure and increasing cardiac output and the cardiac index.

Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments ...

Editor's note: Science Scan is a roundup of recently published biotechnology-relevant research. It's hard to avoid the pitch for Viagra on the television commercials and e-mail spam. Directed at the ...

The progressive worsening of liver cirrhosis and portal hypertension (HTN) decreases intra-hepatic nitric oxide (NO), which is counterbalanced by increased NO secretion from adjacent endothelial cells ...